Slide 1: Investor Presentation
Medicure Inc. Investor Presentation August 27, 2021 MPH:TSXV
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: A Heart For Life
A Heart For Life™ At Medicure, we focus on the heart: cardiovascular pharmaceuticals for the U.S. market Urgent care intervention and preventative therapies 3 MPH:TSXV
Slide 4: What Sets Us Apart
What Sets Us Apart Our approach to engagement and service with healthcare professionals Focusing on value for hospitals, prescribers, and patients 4 MPH:TSXV
Slide 5: Our Vision
WHERE WE ARE GOING Our Vision We want to be a leading cardiovascular pharmaceutical company in the U.S. We have a vertically integrated team, pipeline and acquisitions in place to build growth. We want to be a leading provider of cardiovascular products to U.S. customers We have a vertically integra
Slide 6: Medicure's Acquisition of Marley Drug Pharmacy: The Industry Game-Changer
Medicure’s Acquisition of Marley Drug Pharmacy: The Industry Game-Changer Slides 21-23 MPH:TSXV 6
Slide 7: Our Products and Pipeline
Our Products and Pipeline DEVELOPMENT REGULATORY APPROVED PRODUCT CATEGORY / CLINICAL APPROVAL / MARKETED AGGRASTAT® Hospital IV Injectable Branded antiplatelet, grew from 2% to 65% market share ZYPITAMAG® Prescription Consumer Branded statin with large market potential Sodium Nitroprusside Hospital
Slide 8: Growth Potential: Potential Net Revenue
Growth Potential $60 $50 Potential Net Revenue (MM CAD) $40 BLA NDA ANDA $30 Marley Drug ZYPITAMAG $20 AGGRASTAT $10 $0 2020 2021 2022 2023 2024 MPH:TSXV 8
Slide 9: Five Point Strategic Approach
Five Point Strategic Approach Key Opinion Leaders drive change, and we partner with the best to make that happen Acquisitions of synergistic PARTNER WITH branded or 505b2 approved KOLs cardio products for US market PRODUCT Expand product offering through ACQUISITIONS development of biosimilars, inje
Slide 10: Key Financial Information
Key Financial Information Capital Structure as of August 27th, 2021 • Issued Shares 10,251,313 • Fully Diluted Total 11,073,913 • Share Price C$1.13 • Market Cap C$11.6M Financial Highlights • 2020 Net Revenue $11.6M • 2020 Adj. EBITDA ($3.9M) – investments in sales of 2 new products and R&D • Q2 20
Slide 11: The Story
The Story medicure’
Slide 12: Medicure Leadership Team
Medicure Leadership Team Albert D. Friesen, PhD Neil Owens, PhD David Gurvey, CPA, Reuben Saba, PhD Chief Executive Officer and President and CMA, B.Sc. Vice President, Chairman of the Board Chief Operating Officer Chief Financial Officer Medical and Business Affairs • Founded Medicure in • Joined M
Slide 13: Medicure's History and Trajectory
Medicure’s History and Trajectory 2025 Projected Launch of BLA 2023 Projected Launch of NDA 2023 Projected Launch of ANDA 2020 Acquisition of Marley Drug Pharmacy 2019 Acquisition of ZYPITAMAG, investment in Sensible Medical, launch of Sodium Nitroprusside, SIB returning $26M to investors 2017 AGGRA
Slide 14: AGGRASTAT (tirofiban hydrochloride) Profile
AGGRASTAT® (tirofiban hydrochloride) Profile Estimated Patient Market Share Background: 100% (GP IIb/IIIa Inhibitors) • Hospital product (GP IIb/IIIa inhibitor) for acute cardiovascular care • US rights acquired in 2006 80% • High Dose Bolus (HDB) dosing approved in 2013 • New 15 mL bolus vial forma
Slide 15: AGGRASTAT Sales Update
AGGRASTAT Sales Update Aggrastat Net Revenue By Quarter Aggrastat Units Per Quarter Analysis ($ CAD Millions) 35,000 • Unit Demand in Q2 2021: $4.0 • 11% higher compared to Q1 2021 30,000 $3.5 • 31% higher compared to Q2 2020 25,000 $3.0 • Net Revenue in Q2 2021: 20,000 $2.5 • 6% higher compared to
Slide 16: AGGRASTAT 4-Point Strategic Focus
AGGRASTAT 4-Point Strategic Focus 1. New Indications 3. Marketing As a potent IV antiplatelet agent, we believe Aggrastat can be of benefit in other clinical settings, Significant existing user base as and are investing in new clinical well as market potential remains studies to gain new indications
Slide 17: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Key Information ZYPITAMAG (pitavastatin) A New Type of Statin: • Lowers cholesterol, with some benefits over other statins • Metabolized differently from most other statins • Well tolerated with low rates of muscle pain Acquisition: On September 30, 2019, acquired N
Slide 18: ZYPITAMAG (pitavastatin) Profile
ZYPITAMAG® (pitavastatin) Profile Clinical Differentiation Target Patient Groups Zypitamag is different from most other statins (minimally Of 17 million Americans taking a statin, 5-10% have side effects processed by CYP enzymes) Direct competitor Livalo currently has 0.37% of the statin Reduced ris
Slide 19: ZYPITAMAG Sales Update
ZYPITAMAG Sales Update Zypitamag Net Revenue per Quarter Zypitamag Unit Demand per Quarter Analysis ($ CAD Thousands) • Unit Demand in Q2 2021: 350,000 $450 • 2x higher compared to Q1 2021 $400 • 4x higher compared to Q2 2020 300,000 $350 250,000 $300 • Net Revenue in Q1 2021: • 2.5x higher compared
Slide 20: ZYPITAMAG 4-Point Strategic Focus
ZYPITAMAG 4-Point Strategic Focus 1. Cash Pay Market 3. KOL Engagement Leading KOLs believe Bypass insurance and prior ZYPITAMAG has benefits over authorization process for other statins, and we want to simplicity and certainty of access work with them to spread the for both patients and prescribers
Slide 21: Marley Drug
Key Information Marley Drug • Pharmacy located in North Carolina – licensed to ship medications in 49 states, Washington D.C. and Puerto Rico • Net Revenue in Q2 2021 of $1.87M, compared to $2.1M in Q1 2021 • 30,000 existing customers, with proven success in marketing to consumers based on pricing o
Slide 22: Why Did Medicure Acquire Marley Drug – A Unique Approach
Why Did Medicure Acquire Marley Drug – A Unique Approach 1. Pharmacy with proven success of focus on cash paying customers, and home delivery to 49 States with revenue and profit from low-cost generic drugs 2. A more efficient distribution and marketing vehicle for ZYPITAMAG – a Branded drug 3. A ma
Slide 23: Factors Driving Americans to Pay Cash for Pharmaceuticals
Factors Driving Americans to Pay Cash for Pharmaceuticals 1 2 3 4 5 High Not-Covered or Coverage Gap Deductibles Non-Preferred • More consumers are • High non-preferred • Medicare Part D enrolled in high co-pay ‘donut hole’ or deductible plans Under-Insured • Not covered products, High Cost Share co
Slide 24: Sodium Nitroprusside (SNP)
SODIUM NITROPRUSSIDE (SNP) SNP Units per Quarter Issues 6,000 • Generic product, used in-hospital 5,000 • IV administration, diluted prior to administration 4,000 • Used to rapidly decrease blood pressure in an emergency1 Units 3,000 2,000 • Formulation and fill in a US-facility 1,000 • Seeing uptak
Slide 25: Biosimilar Development
Biosimilar Development Partnership Takeaway’s Timeline • License, Manufacture and • Product Profile: IV cardio • Requires a Phase 3 PK/PD Supply Agreement with product used in-hospital study Reliance Life Sciences (RLS) for a cardiovascular biosimilar • Would be first cardio • Analytical assessment
Slide 26: Development of MC-1 (P5P) for Rare Disease
Development of MC-1 (P5P) for Rare Disease • PNPO deficiency is a rare pediatric disease, which leads to seizures and is fatal if untreated • The disease leads to the inability to produce a critical cofactor (P5P) required for normal development • Currently there is orphan drug status, with no appro
Slide 27: New Cardio Products - Our Target Product Profile
New Cardio Products - Our Target Product Profile In-Hospital Value Urgent care IV products used in Cardio products that can be hospital = build on the licensed or acquired with low or experience, relationships and no initial investment, and if success of AGGRASTAT and licensed can be acquired with s
Slide 28: Investments and Returns to Shareholders
Investments and Returns to Shareholders APICORE (2014-2017) SENSIBLE MEDICAL (2019) SIB (2019) • July 2014 – Acquired 5% interest in • USD $10M investment in Sensible Medical • Completed substantial issuer bid (SIB) Apicore with a 3-year option to in 2019 for $26M in cash purchase the remaining shar
Slide 29: Q2 2021 Financial Results Summary
Q2 2021 Financial Results Summary $ millions CAD Q2 2021 Q1 2021 Q2 2020 Net Revenue 5.1 4.9 2.7 COGS 2.0 1.9 1.5 Selling Expenses 2.5 2.7 0.97 Net Income (loss) (0.64) (1.0) (1.7) FX Gain (loss) (0.17) (0.21) 0.28 Adjusted EBITDA 0.16 0.031 0.26 Context: Increase in revenue in Q2 2021 due to Marley
Slide 30: EBITDA and R&D Investments
EBITDA and R&D Investments Adjusted EBITDA R&D Investments Context for EBITDA and R&D $3,500,000 $2,500,000 • Revenue from AGGRASTAT, ZYPITAMAG and Marley Drug in conjunction with reductions in $1,500,000 selling expenses has started to reverse the trend in Adjusted CAD EBITDA $500,000 • R&D spendin
Slide 31: Key Takeaways About Medicure
5 Key Takeaways About Medicure 1. Medicure’s focus is on cardiovascular pharmaceuticals for the US market 2. Proven success with AGGRASTAT, building sales of ZYPITAMAG with help from Marley Drug subsidiary 3. Pipeline of Cardiovascular Generic, Cardiovascular Biosimilar and MC-1 for Rare Disease 4.
Slide 32: Further Information
Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AggrastatHDB.com 1.888.435.2220 (Ext. 228) Zypitamag.com Marleydrug.com Follow us Contact a Product Specialist Linkedin.com/company/medicure 1.800.509.0544 Twitter.com/MedicureInc Instagram.com/medicureinc MPH:TSX
Slide 33: Important AGGRASTAT Safety Information
Important AGGRASTAT Safety Information Indication: AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Slide 34: Important ZYPITAMAG Safety Information
Important ZYPITAMAG Safety Information IMPORTANT SAFETY INFORMATION FOR ZYPITAMAG (pitavastatin) INDICATIONS & USAGE Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addi
Slide 35: Important Sodium Nitroprusside Safety Information
Important Sodium Nitroprusside Safety Information IMPORTANT SAFETY INFORMATION for Sodium Nitroprusside Injection WARNING - EXCESSIVE HYPOTENSION; Sodium Nitroprusside can cause precipitous decreases in blood pressure. In patients not properly monitored, these decreases can lead to irreversible isch